{"id":"ocrelizumab-dose-1","safety":{"commonSideEffects":[{"rate":"30–40","effect":"Infusion-related reactions"},{"rate":"20–30","effect":"Upper respiratory tract infections"},{"rate":"10–15","effect":"Lower respiratory tract infections"},{"rate":"15–20","effect":"Headache"},{"rate":"10–15","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ocrelizumab targets CD20, a surface antigen expressed on B cells, leading to B cell depletion through antibody-dependent cellular cytotoxicity and direct induction of apoptosis. By eliminating B cells, the drug reduces the production of autoantibodies and pro-inflammatory cytokines, thereby suppressing the autoimmune response underlying multiple sclerosis and other B cell-mediated conditions.","oneSentence":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:36.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444},{"nctId":"NCT06847724","phase":"PHASE3","title":"Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"Sandoz","startDate":"2025-06-10","conditions":"Relapsing Multiple Sclerosis","enrollment":175},{"nctId":"NCT07282574","phase":"PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-10","conditions":"Progressive Multiple Sclerosis","enrollment":360},{"nctId":"NCT04035005","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis, Primary Progressive","enrollment":1013},{"nctId":"NCT04377555","phase":"PHASE4","title":"Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-07-30","conditions":"Multiple Sclerosis, Relapsing","enrollment":179},{"nctId":"NCT03523858","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-05-28","conditions":"Progressive Multiple Sclerosis (PMS)","enrollment":927},{"nctId":"NCT05123703","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-19","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":188},{"nctId":"NCT02649985","phase":"PHASE1, PHASE2","title":"PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2016-05-02","conditions":"Multiple Sclerosis, Alzheimer's Disease","enrollment":250},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT04075266","phase":"PHASE2","title":"A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-09","conditions":"Multiple Sclerosis","enrollment":23},{"nctId":"NCT05131984","phase":"","title":"Ocrelizumab Access by Socio-Economic Status","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-11-18","conditions":"Multiple Sclerosis","enrollment":800},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT05232825","phase":"PHASE3","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-03","conditions":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":236},{"nctId":"NCT03972306","phase":"PHASE1","title":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis (MS)","enrollment":134},{"nctId":"NCT06677710","phase":"PHASE1","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","status":"SUSPENDED","sponsor":"Indapta Therapeutics, INC.","startDate":"2026-06-30","conditions":"Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":34},{"nctId":"NCT03085810","phase":"PHASE3","title":"Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-24","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1225},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT02688985","phase":"PHASE3","title":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-04-29","conditions":"Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive","enrollment":131},{"nctId":"NCT04472975","phase":"","title":"Prescription Drug Safety and Effectiveness in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"1996-01-01","conditions":"Multiple Sclerosis","enrollment":35000},{"nctId":"NCT02545868","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":102},{"nctId":"NCT01412333","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09-20","conditions":"Relapsing Multiple Sclerosis","enrollment":835},{"nctId":"NCT01247324","phase":"PHASE3","title":"A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08-31","conditions":"Relapsing Multiple Sclerosis","enrollment":821},{"nctId":"NCT04295733","phase":"","title":"Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency","status":"COMPLETED","sponsor":"Ospedale Policlinico San Martino","startDate":"2020-02-06","conditions":"Acquired Immunodeficiency","enrollment":98},{"nctId":"NCT03691077","phase":"PHASE3","title":"Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-11-11","conditions":"Multiple Sclerosis, Relapse, Primary Progressive Multiple Sclerosis","enrollment":51},{"nctId":"NCT04855617","phase":"","title":"Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-10-26","conditions":"Multiple Sclerosis","enrollment":122},{"nctId":"NCT05834855","phase":"PHASE3","title":"Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2023-04","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS","enrollment":200},{"nctId":"NCT04971005","phase":"PHASE2","title":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-08-27","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT03589105","phase":"PHASE4","title":"A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-06","conditions":"Multiple Sclerosis","enrollment":423},{"nctId":"NCT03835728","phase":"PHASE2","title":"Efficacy of Ocrelizumab in Autoimmune Encephalitis","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-01-22","conditions":"Autoimmune Encephalitis","enrollment":3},{"nctId":"NCT02980042","phase":"PHASE3","title":"Safety of Switching From Rituximab to Ocrelizumab in MS Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-01-01","conditions":"Multiple Sclerosis","enrollment":200},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT00673920","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-04-24","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT00406419","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2006-12-27","conditions":"Rheumatoid Arthritis","enrollment":1015},{"nctId":"NCT00808210","phase":"PHASE2","title":"A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2009-03-05","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT00485589","phase":"PHASE3","title":"A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-06-11","conditions":"Rheumatoid Arthritis","enrollment":613},{"nctId":"NCT00539838","phase":"PHASE3","title":"A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-12-19","conditions":"Systemic Lupus Erythematosus","enrollment":33},{"nctId":"NCT03606460","phase":"PHASE3","title":"A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2018-09-14","conditions":"Multiple Sclerosis","enrollment":141},{"nctId":"NCT02637856","phase":"PHASE3","title":"A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-02-11","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":608},{"nctId":"NCT00476996","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-05-15","conditions":"Rheumatoid Arthritis","enrollment":836},{"nctId":"NCT02720120","phase":"PHASE1, PHASE2","title":"A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Rheumatoid Arthritis","enrollment":175},{"nctId":"NCT00779220","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Chugai Pharmaceutical","startDate":"2008-10","conditions":"Rheumatoid Arthritis","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ocrelizumab Dose 1","genericName":"Ocrelizumab Dose 1","companyName":"Genentech, Inc.","companyId":"genentech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocrelizumab is a monoclonal antibody that depletes B cells by binding to CD20, reducing autoimmune-mediated inflammation. Used for Relapsing-remitting multiple sclerosis, Primary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}